Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Januar 2018 07:00 ET | Quelle: Shire Pharmaceuticals Group

Shire to present at the 36th Annual J.P. Morgan Healthcare Conference

Shire to present at the 36th Annual J.P. Morgan Healthcare Conference Cambridge, MA - January 4, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, M.D., M.P.H., Chief...
04. Januar 2018 07:00 ET | Quelle: Shire Pharmaceuticals Group

Shire plc : Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients

Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients Cambridge,...
03. Januar 2018 07:00 ET | Quelle: Shire Pharmaceuticals Group

Shire plc : Xiidra® Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease

Xiidra®* (Lifitegrast Ophthalmic Solution 5%) Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease Canada approval represents Shire's first international market...
02. Januar 2018 08:00 ET | Quelle: Shire Pharmaceuticals Group

Shire plc : Total voting rights

Total Voting Rights January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and...
02. Januar 2018 05:01 ET | Quelle: Shire Pharmaceuticals Group

Shire plc : Director Declaration

Director Declaration Dublin, Ireland - January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Dominic Blakemore, Non-Executive Director of the Company, was appointed...
27. Dezember 2017 07:00 ET | Quelle: Shire Pharmaceuticals Group

Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise

Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise Dublin, Ireland - December 27, 2017 - Shire plc (LSE: SHP,...
20. Dezember 2017 07:31 ET | Quelle: Shire Pharmaceuticals Group

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding December 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person...
19. Dezember 2017 07:30 ET | Quelle: Shire Pharmaceuticals Group

SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A

SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A First and only FDA-cleared PK dosing software to support...
19. Dezember 2017 07:01 ET | Quelle: Shire Pharmaceuticals Group

Shire plc : Director Declaration

Director Declaration December 19, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Bill Burns, Senior Independent Director of the Company, was appointed Vice-Chairman...
19. Dezember 2017 07:01 ET | Quelle: Shire Pharmaceuticals Group

Shire Announces Top-Line Results for Phase II/III Clinical Trial in Children with Hunter Syndrome and Cognitive Impairment

Shire Announces Top-Line Results for Phase II/III Clinical Trial in Children with Hunter Syndrome and Cognitive Impairment Cambridge, Ma. - December 19, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG),...

Vorherige Seite